Ondine Biomedical (AIM:OBI) said it has presented results from the SMURF feasibility pilot study at the Canadian Society of Respiratory Therapists Annual Conference, reporting operational feasibility and observed reductions in hospital‑acquired and ventilator‑associated pneumonia that the company says merit further study.
The single‑centre study at Royal Columbian Hospital tested a nasal photodisinfection protocol in critically ill patients and emphasised protocol adherence and practical implementation issues, the company said.
"These results highlight the feasibility of implementing a nasal photodisinfection protocol in a critical care setting and provide intriguing early indications that this approach may help reduce ICU‑acquired infections," Dr Elizabeth Rohrs, the study's principal investigator, said.
The SMURF findings were published in April in Critical Care and were presented at the CSRT meeting held 21-23 May in Whistler.
Ondine noted Steriwave® is CE marked, authorised for nasal decolonisation in Canada, Australia, Mexico and other jurisdictions, has received QIDP and Fast Track designations in the US, and the company recently completed enrolment in its Phase 3 trial.
